COVID-19, MIS-C Associated With COVID-19
Conditions
Keywords
leukocytes, immunophenotype, nasal mucosa, curettage
Brief summary
The aim of the study is to make an accurate assessment of immune cells obtained from nasal mucosa and peripherial blood of MIS-C patients during the disease and the period of health.
Detailed description
The study will consist of two parts. Initially, it will be of a cross-cutting comparative nature, when a group of healthy patients (control group) and a group of patients diagnosed with MIS-C/PIMS syndrome are compared with each other, based on nasal curettage swabs and peripheral blood, before the inclusion of systemic anti-inflammatory treatment (study group). In addition, an observation of the research group will be carried out, during which swabs and peripheral blood will be taken at two more control points.
Interventions
None listed
Sponsors
Erasmus Medical Center
Leiden University Medical Center
Medical University of Warsaw
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
* MIS-C diagnosis based of WHO diagnostic criteria.
Exclusion criteria
* immunosuppressive treatment received up to 3 months before * intranasal drugs received up to 7 days before * COVID-19 vaccination * no consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in leukocyte subpopulations in nasal mucosa and peripherial blood during MIS-C and convalescence. | Three clinical timepoints: (i) baseline (preferably before immunomodulatory treatment), (ii) convalescence, after major symptoms resolution (1 week +/-2 days after treatment introduction), (iii) outpatient control visit (6 weeks after hospital discharge) | The cellular subpopulations will be characterized and clustered using prepared immunomarker array. |
Countries
Poland
Contacts
Primary ContactWojciech Feleszko, MD., PhD
Backup ContactZiemowit Strzelczyk
Outcome results
None listed